Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease

Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease Apolipoprotein ∈ (ApoE)ε4 allele, a risk factor for the development of Alzheimer's disease (AD), is associated with increased amyloid deposition. We examined cerebral cortex in 68 AD cases using antibodies to βbeta;‐amyloid (Aβbeta;) peptides of different length (Aβbeta;1−40 and Aβbeta;l−42) and found that the increased plaque frequency observed with ε4 genotypes may be largely attributed to an increase in Aβbeta;1−40‐positive plaques. Indeed, both the number of Aβbeta;1−40‐positive plaques, as well as the ratio of Aβbeta;I−40/ Aβbeta;1−42‐positive plaques, increased with ε4 dosage. In contrast, the frequency of Aβbeta;1−42‐immunoreactive plaques was similar for ε3/ε3,ε3/ε4 and ε4/ε4 genotypes. ApoE may influence Aβbeta; length by facilitating Aβbeta; 1−40 deposition onto Aβbeta;1−42‐seeded plaques or by modulating the activity of a putative carboxypeptidase that forms Aβbeta;1−40 from Aβbeta;1−42 in situ. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Neurology Wiley

Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease

Loading next page...
 
/lp/wiley/a-peptide-length-aid-apolipoprotein-e-genotype-in-alzheimer-s-disease-O8Pyrv1Xbu

References (46)

Publisher
Wiley
Copyright
Copyright © 1996 American Neurological Association
ISSN
0364-5134
eISSN
1531-8249
DOI
10.1002/ana.410390320
pmid
8602762
Publisher site
See Article on Publisher Site

Abstract

Apolipoprotein ∈ (ApoE)ε4 allele, a risk factor for the development of Alzheimer's disease (AD), is associated with increased amyloid deposition. We examined cerebral cortex in 68 AD cases using antibodies to βbeta;‐amyloid (Aβbeta;) peptides of different length (Aβbeta;1−40 and Aβbeta;l−42) and found that the increased plaque frequency observed with ε4 genotypes may be largely attributed to an increase in Aβbeta;1−40‐positive plaques. Indeed, both the number of Aβbeta;1−40‐positive plaques, as well as the ratio of Aβbeta;I−40/ Aβbeta;1−42‐positive plaques, increased with ε4 dosage. In contrast, the frequency of Aβbeta;1−42‐immunoreactive plaques was similar for ε3/ε3,ε3/ε4 and ε4/ε4 genotypes. ApoE may influence Aβbeta; length by facilitating Aβbeta; 1−40 deposition onto Aβbeta;1−42‐seeded plaques or by modulating the activity of a putative carboxypeptidase that forms Aβbeta;1−40 from Aβbeta;1−42 in situ.

Journal

Annals of NeurologyWiley

Published: Mar 1, 1996

There are no references for this article.